Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5962034 | Indian Heart Journal | 2014 | 4 Pages |
AimA prospective, multicenter, post marketing surveillance study to evaluate the safety and effectiveness of the Superia-Sirolimus Eluting Coronary Stent System (SSECSS) implanted during routine clinical practice in India.ObjectivesPrimary objective:1. To study the MACE and in stent and In-segment Loss at Six Months (in a pre selected group of 50 patients).Secondary objective:1. Clinical and procedural success.Materials and methodsThis is a prospective, open label, single-arm, multicenter (16 sites), post marketing observational study enrolling patients implanted with Superia-Sirolimus Eluting Coronary Stent (SSECS) in routine clinical practice in India. A total of 200 Patients of coronary Artery Disease (CAD) implanted with Superia-Sirolimus Eluting Coronary Stent (SSECS) were enrolled. Clinical assessments were done at 30 days, 180 days and at 1, 2 years either telephonically or office visit. A cohort of 50 pre-selected patients were followed up for angiographic evaluation at 180 days.ResultsMACE at 12 month of follow up was 1.71%.Late lumen loss, in segment was 0.14 and in stent was 0.10Â mm at 6 month of follow-up. TLR was required only in 2 patients.ConclusionSuperia stent is as safe as other biodegradable polymer stent in the market and time has come for biodegradable polymer stent with thin struts.